The Society for Immunotherapy of Cancer (SITC) hosted Session 107b during the 39th Annual Meeting & Pre-Conference Programs on Friday, November 8, 2024. Available here are the presentation slides and video from “Session 107b: Protein and Cellular Engineering Strategies” as permitted by presenters.
Marion Alcantara, MD, PhD – Institut Curie, Paris
Cristina Puig-Saus, PhD – University of California, Los Angeles
Cell and gene therapies have made a great breakthrough in the immuno-oncology field. Technological advances have created opportunities for genetically engineered immune cells to be “redirected” against tumor cells. As such, chimeric antigen receptor (CAR)-T cells are now part of the routine clinical care for many hematological malignancies, but improvements are still needed. A better understanding of the mechanisms of action and the progress in molecular interventions are paving the way for the development of new generations of cellular immunotherapies. Innovative engineering methods will certainly lead to next-generation cell therapies with enhanced efficacy and/or reduced toxicity, notably for targeting low antigen-expressing tumors and solid cancers. This session will focus on genome and protein engineering strategies to optimize cell therapies for hematological and solid tumors.
To view the entire program schedule (including presenter permission to post) please click here.
01:34:42